| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,413,000 |
| Market
Cap: |
9.25(B) |
| Last
Volume: |
538,225 |
Avg
Vol: |
504,506 |
| 52
Week Range: |
$114.17 - $208.42 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$238,260 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
40,296 |
45,669 |
50,307 |
151,828 |
| Total Sell Value |
$7,357,263 |
$8,416,817 |
$9,119,818 |
$30,980,273 |
| Total People Sold |
2 |
4 |
5 |
6 |
| Total Sell Transactions |
3 |
5 |
7 |
17 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hunt Anthony |
Chief Executive Officer |
• • – |
2019-09-09 |
4 |
AS |
$81.26 |
$996,521 |
D/D |
(12,094) |
203,013 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2019-07-15 |
4 |
D |
$85.95 |
$25,355 |
D/D |
(295) |
28,239 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2019-06-17 |
4 |
S |
$77.35 |
$100,168 |
D/D |
(1,295) |
117,034 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2019-06-17 |
4 |
OE |
$4.96 |
$99,200 |
D/D |
20,000 |
118,329 |
|
- |
|
| Cooper Glenn L Md |
Director |
– • – |
2019-05-23 |
4/A |
S |
$66.91 |
$334,715 |
D/D |
(5,000) |
59,709 |
|
- |
|
| Cooper Glenn L Md |
Director |
– • – |
2019-05-23 |
4/A |
OE |
$5.00 |
$120,000 |
D/D |
24,000 |
64,709 |
|
- |
|
| Cooper Glenn L Md |
Director |
– • – |
2019-05-23 |
4 |
S |
$66.91 |
$334,715 |
D/D |
(5,000) |
35,709 |
|
- |
|
| Barthelemy Nicholas |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
5,109 |
|
- |
|
| Cooper Glenn L Md |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
40,709 |
|
- |
|
| Muir Glenn P |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
5,378 |
|
- |
|
| Cox John |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
7,236 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,292 |
98,329 |
|
- |
|
| Ryan Thomas F Jr |
Director |
– • – |
2019-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
923 |
4,148 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2019-03-25 |
4 |
AS |
$58.45 |
$378,602 |
D/D |
(6,467) |
20,534 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2019-03-18 |
4 |
AS |
$59.24 |
$867,633 |
D/D |
(14,550) |
215,107 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2019-03-05 |
4 |
S |
$58.50 |
$760,500 |
D/D |
(13,000) |
229,657 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2019-03-05 |
4 |
S |
$58.53 |
$131,107 |
D/D |
(2,240) |
18,803 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2019-03-05 |
4 |
S |
$58.52 |
$154,785 |
D/D |
(2,645) |
27,001 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
21,043 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
29,646 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2019-02-28 |
4 |
S |
$59.16 |
$10,945 |
D/D |
(185) |
16,343 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
4,234 |
16,528 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2019-02-28 |
4 |
S |
$58.88 |
$110,400 |
D/D |
(1,875) |
24,946 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,922 |
26,821 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2019-02-28 |
4 |
S |
$59.01 |
$441,100 |
D/D |
(7,475) |
242,657 |
|
- |
|
464 Records found
|
|
Page 12 of 19 |
|
|
2.95 (2%) 
